Free Trial

Jasper Therapeutics (JSPR) Competitors

Jasper Therapeutics logo
$3.14 -0.13 (-3.98%)
As of 12:59 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

JSPR vs. NMRA, FDMT, NLTX, EPRX, VTYX, OGI, SLS, YMAB, ALMS, and CTMX

Should you be buying Jasper Therapeutics stock or one of its competitors? The main competitors of Jasper Therapeutics include Neumora Therapeutics (NMRA), 4D Molecular Therapeutics (FDMT), Neoleukin Therapeutics (NLTX), Eupraxia Pharmaceuticals (EPRX), Ventyx Biosciences (VTYX), Organigram Global (OGI), SELLAS Life Sciences Group (SLS), Y-mAbs Therapeutics (YMAB), Alumis (ALMS), and CytomX Therapeutics (CTMX). These companies are all part of the "pharmaceutical products" industry.

Jasper Therapeutics vs. Its Competitors

Neumora Therapeutics (NASDAQ:NMRA) and Jasper Therapeutics (NASDAQ:JSPR) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, risk, media sentiment, valuation, earnings, analyst recommendations, profitability and dividends.

47.7% of Neumora Therapeutics shares are owned by institutional investors. Comparatively, 79.9% of Jasper Therapeutics shares are owned by institutional investors. 26.8% of Neumora Therapeutics shares are owned by insiders. Comparatively, 4.6% of Jasper Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Neumora Therapeutics is trading at a lower price-to-earnings ratio than Jasper Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Neumora TherapeuticsN/AN/A-$243.79M-$1.61-1.24
Jasper TherapeuticsN/AN/A-$71.27M-$5.24-0.60

Neumora Therapeutics currently has a consensus price target of $7.14, suggesting a potential upside of 258.04%. Jasper Therapeutics has a consensus price target of $29.75, suggesting a potential upside of 847.45%. Given Jasper Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Jasper Therapeutics is more favorable than Neumora Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Neumora Therapeutics
1 Sell rating(s)
5 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.22
Jasper Therapeutics
0 Sell rating(s)
4 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.60

Neumora Therapeutics has a beta of 2.75, suggesting that its share price is 175% more volatile than the S&P 500. Comparatively, Jasper Therapeutics has a beta of 2.69, suggesting that its share price is 169% more volatile than the S&P 500.

In the previous week, Jasper Therapeutics had 1 more articles in the media than Neumora Therapeutics. MarketBeat recorded 5 mentions for Jasper Therapeutics and 4 mentions for Neumora Therapeutics. Jasper Therapeutics' average media sentiment score of 0.22 beat Neumora Therapeutics' score of 0.16 indicating that Jasper Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Neumora Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Jasper Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Neumora Therapeutics' return on equity of -84.79% beat Jasper Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Neumora TherapeuticsN/A -84.79% -77.57%
Jasper Therapeutics N/A -109.45%-89.82%

Summary

Jasper Therapeutics beats Neumora Therapeutics on 8 of the 13 factors compared between the two stocks.

Get Jasper Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for JSPR and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding JSPR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

JSPR vs. The Competition

MetricJasper TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$47.16M$3.06B$5.67B$9.49B
Dividend YieldN/A2.44%4.05%3.99%
P/E Ratio-0.6020.7227.8919.99
Price / SalesN/A249.89396.7582.82
Price / CashN/A41.9636.1958.45
Price / Book0.768.288.645.82
Net Income-$71.27M-$55.19M$3.24B$258.39M
7 Day Performance-6.82%4.80%3.11%2.05%
1 Month Performance-43.63%17.28%10.58%12.16%
1 Year Performance-84.87%6.75%34.89%20.90%

Jasper Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
JSPR
Jasper Therapeutics
3.744 of 5 stars
$3.14
-4.0%
$29.75
+847.5%
-84.8%$47.16MN/A-0.6020
NMRA
Neumora Therapeutics
2.51 of 5 stars
$1.27
-1.6%
$7.50
+490.6%
-84.5%$205.42MN/A-0.79108News Coverage
Gap Up
FDMT
4D Molecular Therapeutics
2.3132 of 5 stars
$4.38
+2.3%
$29.56
+574.8%
-73.7%$202.93M$40K-1.38120News Coverage
NLTX
Neoleukin Therapeutics
N/A$21.43
-2.4%
N/A-48.1%$201.40MN/A-6.8990News Coverage
High Trading Volume
EPRX
Eupraxia Pharmaceuticals
2.4908 of 5 stars
$5.59
+4.3%
$11.00
+96.8%
+97.8%$201.02MN/A-7.3629News Coverage
Analyst Forecast
Gap Up
VTYX
Ventyx Biosciences
3.4914 of 5 stars
$2.81
+2.6%
$10.00
+255.9%
+10.1%$199.96MN/A-1.6130
OGI
Organigram Global
0.6691 of 5 stars
$1.48
+2.1%
N/A-11.7%$198.23M$117.47M14.80860
SLS
SELLAS Life Sciences Group
1.644 of 5 stars
$1.98
+7.6%
N/A+56.6%$197.56M$1M-5.2110
YMAB
Y-mAbs Therapeutics
3.1349 of 5 stars
$4.36
flat
$15.60
+257.8%
-62.5%$197.42M$87.68M-6.81150News Coverage
ALMS
Alumis
3.2417 of 5 stars
$3.60
+2.3%
$22.86
+534.9%
-69.5%$195.88MN/A0.00N/ANews Coverage
CTMX
CytomX Therapeutics
3.7895 of 5 stars
$2.39
-1.2%
$5.33
+123.2%
+68.8%$192.68M$138.10M4.98170

Related Companies and Tools


This page (NASDAQ:JSPR) was last updated on 7/24/2025 by MarketBeat.com Staff
From Our Partners